Plain-English translation of NCT05352178 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether combining radiation therapy with hormone-blocking drugs—specifically short-term (ADT) with or without enzalutamide—works better than radiation alone for men whose prostate cancer has come back in only a few spots. Researchers want to know if adding these medications helps prevent the cancer from progressing further and delay the need for long-term hormone therapy.
When prostate cancer returns in just a few spots, doctors can sometimes target those spots with radiation or surgery instead of starting long-term hormone therapy right away. However, it's still unclear whether adding hormone-blocking medications during or after this focused treatment could help the cancer stay away longer and keep men healthier for more years.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to one of three groups: radiation therapy alone, radiation therapy plus one month of hormone-blocking injections, or radiation therapy plus six months of hormone-blocking injections combined with a daily pill called enzalutamide. You will have regular visits to your study team to receive your treatments, have blood tests, and be monitored for side effects. The study will follow you over time to see how long you stay free of cancer progression and when—or if—you eventually need long-term hormone therapy.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
Belgium